ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA) from its SEC filings: 2025 revenue $106.5 million (+351% vs the year before), net margin 78%, free cash flow -$2.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $106.5 million |
| Revenue growth | +351% |
| Net income | $83.2 million |
| Net margin | 78.2% |
| Free cash flow | -$2.4 million |
| Diluted EPS | $1.35 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +53% |
| Cash | $145.3 million |
| Long-term debt | $0 |
| Share count, 1 year | +6% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.